Imagine taking multiple pills every day for decades to keep a chronic condition in check. For many people with HIV, that's been the reality. A new study asked if a simpler, single daily pill could work just as well for those who have already achieved viral suppression on more complex regimens.
The trial involved 557 adults, mostly in their 60s who had been on HIV treatment for a median of 28 years. They were either switched to a new single-tablet regimen called bictegravir-lenacapavir or stayed on their current multi-pill treatment. After 48 weeks, both groups had the same result: only 1% of people in each group saw their viral load rise above a detectable level. The new pill was just as effective at keeping the virus suppressed. Rates of side effects were similar between the two groups.
It's important to note that the study was open-label, meaning both participants and doctors knew which treatment they were on, which can sometimes influence how people report their experiences. While the results are promising for simplifying treatment, the study only followed people for 48 weeks. We don't yet know the long-term safety profile of this new combination. Five people in the single-pill group died during the study, though none of the deaths were judged to be related to the study drug.